Valeant Pharmaceuticals International, Inc.
Specialty pharmaceutical roll-up that used undisclosed captive specialty pharmacy Philidor Rx Services to stuff channels and accelerate revenues.
- Entity Name: Valeant Pharmaceuticals International, Inc.
- Country of Domicile: CA
- Listing & Ticker: NYSE (VRX).
- CIK / LEI Identifier: 0000885590.
- Industry Classification: Pharmaceutical Preparations (SIC 2834).
- Cumulative Overstatement: $58.0M across 1 enforcement episode(s).
- Assessed Penalties: $45.0M.
PRIMARY ENFORCEMENT CASES INVOLVING VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
1 CASE DOSSIERS| Case Title | Status | Primary Scheme | Overstatement | Total Penalties | Action Date |
|---|---|---|---|---|---|
| Valeant Pharmaceuticals: Undisclosed Captive Pharmacy Philidor and Channel Stuffing | Settled, neither admitted nor denied | channel stuffing | $58.0M | $45.0M | September 20, 2017 |
FORENSIC PROFILE: VALEANT PHARMACEUTICALS: UNDISCLOSED CAPTIVE PHARMACY PHILIDOR AND CHANNEL STUFFING
FULL CASE DOSSIER →Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels.
The company manipulated its accounting records by executing schemes under channel-stuffing. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.
Fraud Window: January 1, 2015 to December 31, 2017 • Primary Regulator: U.S. Securities and Exchange Commission • Auditor: PricewaterhouseCoopers LLP
Documented Accounting Irregularities & Regulatory Findings
- CHANNEL STUFFING: Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels.
Primary Public Dockets & Actions
- [ENF-2015-valeant] Enforcement Action: Valeant Pharmaceuticals: Undisclosed Captive Pharmacy Philidor and Channel Stuffing (September 20, 2017): Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels. Official Record ↗